Advanced Medical Isotope Corporation Announces Board of Directors Appointment
KENNEWICK, Wash., Sept. 11, 2012 (GLOBE NEWSWIRE) -- Advanced Medical Isotope
Corporation ("AMIC") (OTCBB:ADMD), a company engaged in the production and
distribution of medical isotopes, has added one of the region's top medical
device entrepreneurs, Thomas J. Clement, to the Board of Directors. Clement
has over 30 years experience in product development engineering, engineering
management, and senior management. He was a founding employee of Heart
Technology, which grew to more than $100 million in revenue and was acquired
by Boston Scientific. In 1998 Clement co-founded Pathway Medical Technologies,
Inc. Serving as CEO, he successfully raised more than $84 million. Pathway was
acquired by Bayer Healthcare of Germany in 2011.
Tom Clement has recently held the positions of Chairman of the Washington
State Biotechnology and Biomed Association (WBBA) as well as the Director of
New Ventures-Life Sciences for the University of Washington's Center for
Commercialization. Tom is currently the CEO of two start-up companies, Cardiac
Insight, Inc., and Aqueduct Neurosciences, Inc. and is on the Board of
Directors of several medical technology companies.
Further, Mr. Clement serves as a Governor appointed Board member for the
Washington Global Health Fund and an Advisory Board Member on the Visiting
Committee for the University of Washington's Educational Outreach Programs.
Clement has a Master of Science in Electrical Engineering from the University
of Washington, and an Executive MBA from Stanford.
"I'm honored and delighted to be elected to the Board of Directors of AMIC. I
will do my best to add significant value towards the implementation of the
dynamic business plan that AMIC is pursuing," said Clement.
James C. Katzaroff, CEO of AMIC, stated, "My position on the Board of
Directors of the WBBA has afforded me the opportunity to get to know Tom
Clement, as well as for Tom to understand the exciting path forward that AMIC
is strategically implementing. Tom's experiences and business acumen
complements our future growth plans and I look forward to working closely with
him to execute our next phase of growth."
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (AMIC)(OTCBB:ADMD) is a U.S.-based public
company engaged in the production and distribution of medical isotopes and in
the development and identification of medical isotope technologies that are
changing the practice of medicine and revolutionizing the standard of medical
The Advanced Medical Isotope Corporation logo is available at
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934 and Section 27A of the
Securities Act of 1933, including, but not limited to, statements related to
AMIC's beliefs and expectations regarding its licensed patents. These
statements involve current expectations and beliefs as to future events and
other statements that are not historical facts. Known and unknown risks and
uncertainties can affect the accuracy of forward-looking statements and cause
actual results to differ materially from those anticipated by these
forward-looking statements. Factors that could affect actual future events or
results include, but are not limited to, risks relating to product
development, regulatory approval, sales and marketing, and competition, risks
relating to patents, and such other risks as are defined in AMIC's annual
report filed by AMIC with the U.S. Securities and Exchange Commission. These
forward-looking statements apply only as of the date of this press release,
and AMIC undertakes no duty to publicly announce or report revisions to these
statements as new information becomes available that may change AMIC's
CONTACT: Advanced Medical Isotope Corporation
James C. Katzaroff
6208 W. Okanogan Ave.
Kennewick, Wa. 99336
Press spacebar to pause and continue. Press esc to stop.